---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-292799"
form_type: "8-K"
ticker: "IRON"
cik: "0001816736"
company_name: "Disc Medicine, Inc."
filed_at: "2023-12-12T23:59:59+00:00"
generated_at: "2026-06-07T14:20:13.850115+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Disc Medicine reports positive updated Phase 2 BEACON data for bitopertin; PPIX drops >40%, sunlight tolerance improves

## Summary
- PPIX levels reduced >40% (p<0.001) from baseline; sustained and dose-dependent in 22 EPP patients.
- Time to prodrome improved >3x; proportion of days without symptoms rose to 78% vs 33% baseline.
- Mean cumulative time in light over 6 months: 222.6 hours (>3x historical control) on precedented pivotal endpoint.
- Bitopertin well-tolerated with no serious AEs; stable mean hemoglobin, no anemia events reported.
- Initial positive Phase 1b data for DISC-0974 in myelofibrosis showed hemoglobin improvements and reduced transfusions.

## SEC filing metadata
- accession: 0001193125-23-292799
- form_type: 8-K
- ticker: IRON
- cik: 0001816736
- company_name: Disc Medicine, Inc.
- filed_at: 2023-12-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1816736/000119312523292799/0001193125-23-292799-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1816736/000119312523292799/d638553d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-292799
- JSON: https://secwatch.observer/filing/0001193125-23-292799.json
- Plain text: https://secwatch.observer/filing/0001193125-23-292799.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.